Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC

NCT02382406 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

46

Enrollment

OTHER

Sponsor class

Stopped The study was completed. It was fully accrued.

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Carboplatin
DRUG: Nab-paclitaxel
DRUG: MK-3475 (Phase I)
DRUG: MK-3475 (Phase II)

Sponsor

Nisha Mohindra, MD

Collaborators

[object Object]
[object Object]
[object Object]